Bortezomib causes hepatic impairement in four patients with multiple myeloma

VernacularTitle:硼替佐米治疗多发性骨髓瘤发生药物性肝损害四例
Author: Ying HU ; Shilun CHEN ; Yuping ZHONG ; Xin LI ; Na AN ; Jiajia ZHANG ; Xiaohui LIU
Publication Type:Journal Article
Keywords: Multiple myeloma; Hepatic impairment; Drug toxicity
From: Journal of Leukemia & Lymphoma 2010;19(7):425-426,431
CountryChina
Language:Chinese
Abstract: Objective To obserue that bortezomib lead to hepatic impairment and even hepatic insufficiency. Methods Four multiple myeloma patients with hepatic impairment in velcade therapy were analyzed. All of 4 patients ranged from 46 to 60-year-old were relapsed and refractory, including 3 cases of male and 1 of female; 2 of K light chain type, 1 of non secretion type and 1 of IgGλλ biclonal type; 3 in stage ⅢB and 1 in stage ⅢA. Results Four patients had normal hepatic function before bortezomib therapy, but all appeared hepatic impairment during therapy. ALT and aspartate aminotransferase were increased by 2-80 and 1.5-70 times compared with before the chemotherapy, respectively, and bilirubin and alkaline phosphatase in 2 patients and glutamyltranspeptidase in 1 patient were increased. Hepatic function restored normally after patients were given liver securing drug and discontinued bortezomib therapy. Conclusion It isn't rare that bortezomib causing hepatic impairment in the patients with multiple myeloma.